Thank you very much.
I'd like to come back to one of the points you made, Matthew. You laid out your four points about transparency, registration of all clinical trials, that there should be mandatory disclosure of all studies and reports, penalties for non-compliance, but the third one, Health Canada to report all decisions and the reasons behind the decisions.
I think we've been looking at this issue and sort of saying there has to be a lot of onus on the pharmaceutical companies and so on, which clearly is critical. In fact, the more we learn about this issue, the more it is so disturbing about how little knowledge there is in the public realm about what goes on. Hopefully, this bill will be able to address that.
In terms of the role that Health Canada plays, we haven't focused on this a lot. What happens now? If your amendment or your suggestion is incorporated, how would you actually see that working in terms of timeliness in getting information out? You may be familiar that the Auditor General, in 2011, issued a report saying that it could take up to two years, even under the status quo, for information to get out to people about adverse reactions.
If we adopted this in principle and tried to get an amendment, how would you see it working in terms of ensuring that there's a streamlined flow of information, and that the system doesn't become, in effect, paralyzed because everybody is waiting for somebody else to get their piece of information out there?